Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      Ireland/Our innovation /Focus areas/Oncology

      Oncology

      At Johnson & Johnson Oncology, we understand that the power to change the lives of those with cancer begins with a very considered step. Forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of Purposeᵀᴹ.

      Despite the incredible work of the oncology community across Europe, cancer remains the second leading cause of premature death in Europe.[1][2] We fiercely believe cancer is a challenge we can collectively overcome, and our ultimate aim is to make cancer an interceptable, even curable, or chronic disease. We know that receiving a cancer diagnosis can be overwhelming and sparks fear. We are striving to change this, so that one day the words “you have cancer” will be less terrifying for patients to hear and less distressing for healthcare professionals to say and act upon.
      JJ_Photo_Patient hugging family in hospital_JJ_3Star.jpg
      Our precise purpose
      Every cancer is different, each possessing unique challenges along the way.[3] But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference for patients, partners, and the entire oncology community. To do this, we consistently integrate patients’ perspectives into everything we do.
      Our oncology areas of focus
      Our pipeline is taking science from where it is to where it has not been before, through targeted transformation.
      Multiple myeloma .webp
      Multiple myeloma
      We want to improve treatment efficacy for patients with this rare, incurable blood cancer.
      B-cell malignancies.webp
      B-cell malignancies
      There are many different types of B cell malignancies.[4] We’re focused on five main types.
      Prostate cancer.webp
      Prostate cancer
      We have many years experience in research in prostate cancer, the most common cancer among men in the EU.
      Bladder cancer.webp
      Bladder cancer
      Despite therapies being available, there is a high unmet need in bladder cancer due to poor outcomes. We are striving to change that.[5][6]
      Lung cancer.webp
      Lung cancer
      We’re concentrating on developing targeted therapies for patients with lung cancer, the leading cause of cancer death for men and women globally. [7]

      References

      [1] World Health Organization Regional Office for Europe. Cancer data and statistics. Available at https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1 Accessed October 2024.
      [2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387.
      [3] Ogino S. et al. Expert Rev Mol Diagn. 2012; 12(6): 621–628. 2 TBC
      [4] WebMD. What is B-Cell Lymphona. Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma Accessed October 2024.
      [5] European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC-White-Paper-Bladder-Cancer-EN-1.pdf Accessed October 2024.
      [6] Kamaneh Montazeri & Joaquim Bellmunt. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1):1-6.
      [7] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed October 2024.

      CP-485329 l October 2024